CPT® Code 81422

Fetal chromosomal microdeletion(s) genomic sequence analysis (eg, DiGeorge syndrome, Cri-du-chat syndrome), circulating cell-free fetal DNA in maternal blood

The CPT® Code 81422 refers to a specific laboratory test known as fetal chromosomal microdeletion(s) genomic sequence analysis. This test is performed on circulating cell-free fetal DNA found in maternal blood. The primary purpose of this analysis is to detect chromosomal abnormalities that may be associated with various genetic conditions, including DiGeorge syndrome and Cri-du-chat syndrome. These conditions arise from specific chromosomal microdeletions, which are small missing segments of DNA that can lead to significant developmental issues. The test is particularly relevant for identifying aneuploidies, which are conditions where there is an abnormal number of chromosomes, such as trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome), as well as monosomy X (Turner syndrome). The procedure involves obtaining a blood sample from the mother, which is then analyzed for fetal DNA fragments using advanced techniques such as targeted sequencing and single-nucleotide polymorphism analysis. This non-invasive approach allows for the assessment of fetal genetic material without the need for more invasive procedures, making it a valuable tool in prenatal care. The test is particularly indicated for women who meet certain criteria, such as being over the age of 35, having elevated levels of maternal free beta-hCG, or having abnormal ultrasound findings that suggest the possibility of fetal aneuploidy. Additionally, a maternal history of previous pregnancies affected by aneuploidy may also warrant this testing. Positive results from this analysis may lead to further genetic testing options, such as chorionic villus sampling or amniocentesis, to confirm any findings and provide more comprehensive information regarding the fetus's genetic health.